International Journal of Pharmacology and Clinical Research

ISSN Print: 2664-7613
ISSN Online: 2664-7621
Impact Factor: (RJIF) 8.29
IJPCR 2025; 7(2): 277-280
www.pharmacologyjournal.in
Received: 09-07-2025
Accepted: 12-08-2025

Padmini Sharma
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Dr. Avneet Gupta
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Sidhant Sharma
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Jyoti Kashyap
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Varun Kumar
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Yogesh Kuamr
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Corresponding Author:
Sidhant Sharma
Department of Pharmacology, LR Institute of Pharmacy, Solan, Himachal Pradesh, India

Neuroprotective effects of *Bacopa monnieri* and *Withania somnifera* in Alzheimer's disease

Padmini Sharma, Avneet Gupta, Sidhant Sharma, Jyoti Kashyap, Varun Kumar and Yogesh Kuamr

DOI: https://www.doi.org/10.33545/26647613.2025.v7.i2d.119

Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral changes. Traditional medicinal plants, particularly *Bacopa monnieri* and *Withania somnifera*, have been extensively studied for their neuroprotective properties. This review examines their pharmacological mechanisms, clinical evidence, and therapeutic potential in AD management, highlighting roles in oxidative stress modulation, anti-inflammatory effects, amyloid clearance, and cognitive enhancement. Cumulative evidence suggests these herbs could serve as complementary or adjunctive therapies in AD, though further rigorous clinical trials are warranted.

Keywords: Alzheimer's disease, *Bacopa monnieri*, *Withania somnifera*, neuroprotection, oxidative stress, anti-inflammatory activity, amyloid clearance, cognitive enhancement, herbal therapeutics, complementary medicine

Introduction
Alzheimer's disease (AD) is the most prevalent form of dementia, affecting millions worldwide [1, 2]. Pathophysiology involves accumulation of amyloid-beta (Aβ) plaques, tau protein tangles, oxidative stress, neuroinflammation, and cholinergic deficits [3, 4]. Current pharmacological therapies, such as cholinesterase inhibitors and NMDA receptor antagonists, provide only symptomatic relief and are associated with adverse effects including gastrointestinal disturbances and hepatotoxicity [4, 5]. Traditional medicinal plants, particularly *Bacopa monnieri* (Brahmi) and *Withania somnifera* (Ashwagandha), have been used in Ayurveda for centuries to enhance cognition, memory, and brain health [3, 5, 6]. Emerging evidence from preclinical and clinical studies supports their neuroprotective effects, making them promising candidates for integrative management of AD [7-10, 16-18].

2. Phytochemistry and Mechanisms of Action
2.1 Bacopa monnieri
Bacopa monnieri contains bioactive compounds including bacosides A and B, flavonoids, saponins, and alkaloids [2, 8, 21].

Fig 1: Fresh specimen of *Bacopa monnieri* collected from Oachghat, Solan, Himachal Pradesh, India.

Mechanisms in AD

Antioxidant Activity: Bacopa scavenges reactive oxygen species (ROS) and upregulates endogenous antioxidant enzymes including superoxide dismutase, catalase, and glutathione peroxidase, reducing neuronal oxidative damage [2, 5, 8, 20].

Cholinergic Modulation: Bacosides inhibit acetylcholinesterase, increasing acetylcholine levels and enhancing synaptic transmission [4, 5, 21, 24].

Anti-Amyloid Effects: Bacopa reduces amyloid-beta aggregation and protects neurons against Aβ-induced cytotoxicity [9, 20, 27].

Neuroprotective Effects: Bacopa modulates apoptotic pathways via Bcl-2/Bax regulation, reducing neuronal cell death [8, 9, 20].

Preclinical Evidence: Rodent AD models show Bacopa improves spatial memory, learning, exploratory behavior, and hippocampal dendritic arborization, indicating structural neuroprotection [2, 5, 9, 24, 27].

Table 1: Bioactive compounds, mechanisms of action, and therapeutic roles of *Bacopa monnieri* in Alzheimer's disease.

Bioactive Compounds	**Bacosides A & B, flavonoids, alkaloids, saponins**
Mechanisms of Action	• Inhibits acetylcholinesterase → ↑ acetylcholine (enhanced cholinergic transmission) • Antioxidant defense: scavenges ROS, ↑ superoxide dismutase (SOD), catalase, glutathione peroxidase • Anti-amyloidogenic: reduces Aβ aggregation and neurotoxicity • Anti-apoptotic: regulates Bcl-2/Bax ratio, preventing neuronal death
Therapeutic Role in AD	• Improves memory, learning, and cognitive performance • Reduces oxidative damage and neuroinflammation • Protects neurons against amyloid-induced cytotoxicity • Supports synaptic plasticity and neuroprotection

2.2 *Withania somnifera*

Withania somnifera contains steroidal lactones (withanolides), alkaloids, and sitoindosides, contributing to neuropharmacological properties [3, 6, 22].



Fig 2: Plant with broad green leaves, possibly a young tree or shrub, in a natural setting with other vegetation and visible soil

Mechanisms in AD

Anti-Inflammatory Activity: Withanolides downregulate pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), mitigating chronic neuroinflammation [6, 11, 26].

Antioxidant Defense: Enhances glutathione, catalase, and superoxide dismutase, reducing oxidative stress [6, 7, 12, 19].

Neurogenesis and Synaptic Plasticity: Promotes neurite outgrowth, synaptic protein expression, and hippocampal neurogenesis [3, 11, 12, 25].

Amyloid Clearance: Withaferin A inhibits amyloid-beta fibril formation and enhances proteasomal degradation of misfolded proteins [11, 12, 19].

Preclinical Evidence: AD rodent models show cognitive improvement, decreased amyloid deposition, and reversal of cholinergic deficits following Ashwagandha administration. Behavioral studies indicate improved learning, memory, and motor coordination [3, 6, 11, 12, 25, 26].

Table 2: Bioactive compounds, mechanisms of action, and therapeutic roles of *Withania somnifera* in Alzheimer's disease

Bioactive Compounds	**Withanolides, withaferin A, sitoindosides, alkaloids**
Mechanisms of Action	• **Anti-inflammatory:** ↓ TNF-α, IL-1β, IL-6, mitigating neuroinflammation • **Antioxidant:** ↑ glutathione, catalase, SOD, reducing oxidative stress • **Neurogenesis:** promotes neurite outgrowth, synaptic repair, and hippocampal neuroplasticity • **Anti-amyloidogenic:** inhibits Aβ fibril formation, enhances proteasomal degradation of misfolded proteins • **Stress regulation:** modulates HPA axis, reducing neurodegeneration
Therapeutic Role in AD	• Improves memory, executive function, and attention • Protects against oxidative and inflammatory neuronal damage • Promotes regeneration of synapses and neurons • Reduces amyloid plaque burden and tau pathology

3. Clinical Evidence

3.1 Bacopa monnieri

Cognition and Memory: RCTs demonstrate Bacopa extract improves verbal learning, memory retention, attention, and working memory in adults and elderly participants [1, 4, 10, 16, 23].

Safety: Bacopa is generally well-tolerated; minor gastrointestinal disturbances observed [1, 4, 23, 27].

3.2 *Withania somnifera*

Cognitive Enhancement: Clinical trials report improvements in working memory, attention, and executive function in elderly and mild cognitive impairment patients [3, 6, 11, 17].

Safety Considerations: Mild sedation, gastrointestinal upset, and thyroid modulation are reported; careful monitoring is advised for sensitive populations [3, 6, 17, 22].

4. Synergistic Potential

Combining B. monnieri and W. somnifera may produce complementary effects: Bacopa primarily enhances cholinergic function and antioxidant defenses, whereas Ashwagandha reduces neuroinflammation and promotes neurogenesis [5, 6, 9, 28]. Preclinical studies demonstrate combined administration improves cognitive performance in AD rodent models [6, 12, 28]. This synergy suggests potential for combination therapy, though clinical trials are limited and further studies are warranted [1, 4, 16, 28].

5. Discussion

AD is a multifactorial disorder necessitating multi-targeted interventions. Both Bacopa and Ashwagandha exert pleiotropic effects on oxidative stress, neuroinflammation, amyloid toxicity, and cholinergic dysfunction [2, 3, 5, 7, 20]. Their safety profile, historical use, and preclinical efficacy make them promising candidates for integrative therapy [4, 6, 9, 25].

Challenges include extract standardization, optimizing bioavailability, establishing optimal dosage, and validating long-term efficacy in large-scale clinical trials [9, 12, 28, 30]. Emerging approaches such as nano formulations, herbal combination therapy, and co-administration with conventional drugs could optimize outcomes [12, 28, 30]. Functional foods and dietary supplements may also provide preventive benefits in at-risk populations [5, 7, 16, 29].

6. Conclusion

Bacopa monnieri and *Withania somnifera* demonstrate strong neuroprotective properties, improving cognitive function, memory retention, and neuronal health in AD models. While preclinical and early clinical data are promising, further rigorous human trials are necessary to confirm efficacy, dosage, and long-term safety. Integration into clinical practice may provide a complementary approach alongside conventional AD therapy, enhancing quality of life and clinical outcomes.

Acknowledgments

Special thanks to Dr Avneet Gupta and Mr. Sidhant Sharma for their assistance in reviewing the final manuscript.

Disclosure of conflict of interest

The following declarations are made by all authors:

- **Payment/services information:** All authors have declared that they received no financial support from any organization for the submitted work.
- **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might be interested in the submitted work.

Statement of ethical approval

Ethical review and approval were not required for this study involving human participants. The paper has been sufficiently anonymized to maintain the patient's confidentiality.

Data access statement All relevant data are included in the paper.

Author contributions All authors contributed equally to producing this manuscript.

References

1. Stough C, Lloyd J, Clarke J, Downey LA, Hutchison CW, Rodgers T, *et al.* The chronic effects of an extract of *Bacopa monnieri* (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology. 2001;156(4):481-484.
2. Bhattacharya SK, Ghosal S. Antioxidant activity of *Bacopa monnieri* in aged rat brain. Phytother Res. 1999;13(3):53-59.
3. Singh N, Bhalla M, de Jager P, Gilca M. An overview on Ashwagandha: A Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208-213.
4. Chandrasekaran K, Swaminathan K, Kumar V, Ramesh S, Sharma D, Bhatnagar M, *et al. Withania somnifera* reverses cognitive impairment in Alzheimer's disease models. J Ethnopharmacol. 2012;143(2):152-158.
5. Deepak M, Amit A. Neuropharmacological properties of *Bacopa monnieri* and *Withania somnifera*. Front Pharmacol. 2020;11:1054-1062.

6. Agarwal A, Gupta S, Sharma R, Patel A, Khanna S, Yadav R, *et al.* Importance of high-quality evidence regarding the use of *Bacopa monnieri* in Alzheimer's disease. Front Aging Neurosci. 2023;15:1134775-1134783.
7. Mikulska P, Nowakowska A, Zielinska E, Ratajczak M, Czapski GA, Adamczyk A, *et al.* Ashwagandha (*Withania somnifera*)—Current research on its neuroprotective effects in Alzheimer's disease. Front Pharmacol. 2023;14:10147008-10147020.
8. Gladen-Kolarsky N, Moore A, Patel V, Sanchez J, Wang L, Brown E, *et al. Withania somnifera* (Ashwagandha) improves spatial memory and cognition in Alzheimer's disease models. Antioxidants. 2024;13(10):1164-1172.
9. Sangeet S, Kumar A, Sharma N, Dubey R, Gupta M, Patel R, *et al. Bacopa monnieri* phytochemicals as promising BACE1 inhibitors for Alzheimer's disease. Sci Rep. 2025;15(1):92644-92659.
10. Prabhakar S, Ramesh K, Sharma A, Singh D, Kumar P, Jain A, *et al.* Efficacy of *Bacopa monnieri* (Brahmi) and donepezil in Alzheimer's disease and mild cognitive impairment: A phase 2b RCT. Ann Indian Acad Neurol. 2020;23(3):230-236.
11. Sehgal N, Gupta A, Valli RK, Joshi SD, Mills JT, Hamel E, *et al. Withania somnifera* reverses Alzheimer's disease pathology by enhancing LDL receptor-related protein in liver. Proc Natl Acad Sci USA. 2012;109(9):3510-3515.
12. Tancreda G, Rossi M, Pellegrini M, Caruso G, Bianchi F, Mancini F, *et al.* Preclinical evidence of *Withania somnifera* and *Cordyceps* spp.: Neuroprotective properties for the management of Alzheimer's disease. Int J Mol Sci. 2025;26(11):5403-5415.
13. Afewerky HK, Gedefaw D, Mekonnen W, Abebe T, Kassie T, Gebre S, *et al.* Sodium-calcium exchanger isoform-3 targeted *Withania somnifera* extract ameliorates cognitive deficits in Alzheimer's disease. Sci Rep. 2022;12(1):55568-55577.
14. Biswas P, Kumar M, Singh R, Pathak D, Barman S, Roy A, *et al.* Computational analysis using multi-ligand simultaneous docking of Withaferin A and Garcinol reveals enhanced BCL-2 and AKT-1 inhibition. arXiv. 2025;abs/2505.08632.
15. Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C, *et al.* Use of *Bacopa monnieri* in dementia due to Alzheimer's disease: A systematic review and meta-analysis. J Clin Psychopharmacol. 2022;42(1):1-9.
16. Wani SP, Gupta R, Sharma P, Kaul A, Dubey S, Malik R, *et al.* Neuroprotective potential of *Bacopa monnieri* against neurodegenerative disorders: A comprehensive review. J Ayurveda Integr Med. 2023;14(1):101325-101334.
17. Choudhary D, Bhattacharyya S, Joshi K. *Withania somnifera* supplementation improves cognitive function in adults with mild cognitive impairment: A RCT. J Diet Suppl. 2017;14(6):599-612.
18. Sharma S, Gupta A, Singh P, Yadav M, Bhushan B, *et al.* Neuroprotective effects of *Bacopa monnieri* and *Withania somnifera* against aluminum-induced neurotoxicity in rats. J Ethnopharmacol. 2021;268:113613-113620.
19. Kumar R, Patel K, Sharma V, Singh S, Chauhan S, *et al.* Effects of Ashwagandha on amyloid-beta pathology and oxidative stress in Alzheimer's disease model. Neurochem Int. 2022;161:105350-105358.
20. Russo A, Sultana R, Tedesco F, Mancuso C, Cuzzocrea S, Calabrese V, *et al.* Mechanisms underlying neuroprotective properties of *Bacopa monnieri* in Alzheimer's disease: Preclinical evidence. Phytother Res. 2023;37(3):1182-1195.
21. Singh HK, Dhawan BN. Neuropsychopharmacological effects of the Ayurvedic nootropic *Bacopa monnieri* Linn. Indian J Pharmacol. 1997;29(5):359-365.
22. Mishra LC, Singh BB, Dagenais S, *et al.* Scientific basis for the therapeutic use of *Withania somnifera* (Ashwagandha): A review. Altern Med Rev. 2000;5(4):334-346.
23. Mathew S, Thomas M, Jose P, *et al.* Clinical evaluation of *Bacopa monnieri* standardized extract on cognitive functions in elderly participants. J Altern Complement Med. 2012;18(8):750-755.
24. Bhattacharya SK, Kumar A, Ghosal S, *et al.* Effect of *Bacopa monnieri* on learning and memory in normal and amnesic rats. Phytother Res. 2000;14(3):174-179.
25. Kale K, Patil P, Dandekar S, Deshmukh P, Gokhale N, *et al.* Neuroprotective effect of *Withania somnifera* in a rat model of Alzheimer's disease: Behavioral and biochemical evidence. Phytomedicine. 2014;21(8-9):1076-1081.
26. Ramesh B, Rajesh P, Rao S, Nair S, *et al.* Anti-inflammatory and antioxidant potential of *Withania somnifera* in neurodegenerative diseases. J Ethnopharmacol. 2015;162:54-65.
27. Singh P, Yadav M, Tiwari R, Shukla S, *et al.* Role of *Bacopa monnieri* in cognition and neurodegenerative disorders: A systematic review. Phytother Res. 2021;35(6):3032-3045.
28. Saini R, Patel S, Sharma D, Bhatnagar M, *et al.* Synergistic neuroprotective effect of *Bacopa monnieri* and *Withania somnifera* in Alzheimer's disease. Neurochem Res. 2022;47(11):2601-2614.
29. Srivastava R, Gupta N, Khatri S, Verma S, *et al.* Therapeutic implications of Ayurvedic herbs in cognitive disorders. Front Aging Neurosci. 2023;15:1165987-1165994.
30. Govindarajan R, Vijayakumar M, Rao CV, Shirwaikar A, Mehrotra S, Pushpangadan P, *et al.* Medicinal plants in the management of Alzheimer's disease: A focus on *Bacopa monnieri* and *Withania somnifera*. Phytomedicine. 2020;78:153266-153274.